GlassScriptPhysician profile
Emad Awa
NPI 1336408723
$2,059.43
in general payments reported to CMS, 2019-2025
20 companies · $343 in 2025
The $343 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.61 · 2020: $51.11 · 2021: $178 · 2022: $314 · 2023: $648 · 2024: $474 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,465.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $428.92 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $227.90 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $219.66 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $178.30 | 2020-2024 | |
| Collegium Pharmaceutical, INC. | $142.08 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $130.03 | 2019-2025 | Bexsero, Rotarix, Fluarix Quadrivalent |
| Cranial Technologies, INC | $115.66 | 2023-2025 | Doc Band |
| Tris Pharma INC | $114.40 | 2021-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $108.61 | 2019-2025 | Gardasil 9, M-M-R II, Vaxelis |
| Verrica Pharmaceuticals INC. | $72.63 | 2023-2024 | Ycanth |
| Otsuka America Pharmaceutical, INC. | $60.15 | 2021-2022 | |
| Neos Therapeutics, LP | $53.47 | 2020-2024 | Adzenys Xr-Odt |
| Avion Pharmaceuticals | $40.96 | 2023-2024 | Methylphenidate Hydrochloride |
| Astrazeneca Pharmaceuticals LP | $40.50 | 2022-2023 | Flumist Quadrivalent |
| Alexion Pharmaceuticals, INC. | $39.13 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $22.81 | 2021 | |
| Vertical Pharmaceuticals, LLC | $19.95 | 2024 | Relexxii |
| Kowa Pharmaceuticals America, INC. | $15.50 | 2025 | Zoryve |
| Nestle Healthcare Nutrition INC. | $14.86 | 2021 | |
| Alk-Abello, INC | $13.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emad Awa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.